




PHARMACEUTICAL 2021

Alaunos Therapeutics Inc.
Rank 143 of 402





RealRate

PHARMACEUTICAL 2021

Alaunos Therapeutics Inc. Rank 143 of 402



The relative strengths and weaknesses of Alaunos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Alaunos Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 158%, being 111% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	130,589
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,368
Liabilities, Non-Current	0
Other Assets	5,525
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,995
Other Net Income	385
Other Revenues	0
Property and Equipment	10,231
Research and Development	52,696
Selling, General and Administrative Expense	27,665

Output Variable	Value in 1000 USD
Assets	146,345
Liabilities	22,363
Expenses	80,361
Revenues	0
Stockholders Equity	123,982
Net Income	-79,976
Comprehensive Net Income	-79,976
Economic Capital Ratio	158%